Can genes predict chemo success in pancreatic cancer?
NCT ID NCT03977233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (like basal-like or classical) influence how well the cancer shrinks or becomes removable. The goal is to improve disease control and surgical outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF PANCREAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new imaging trick spot pancreatic cancer without a biopsy?
- Can a pill rouse the immune system against pancreatic cancer?
- Can zapping pancreatic tumors with heat before surgery boost Chemo's power?
- Can a radioactive tracer light up hidden tumors? a new trial aims to find out
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Breath of life: new test could sniff out gut cancers before they spread